Biosciences Partnering and Licensing Opportunities

SRI has a number of drug candidates that are available for partnering and SRI owns the intellectual property surrounding these compounds. To download an introductory overview, please click the links below. The files are loaded in Adobe Acrobat PDF format.

• SR13668: Novel Indole for the Treatment of Cancer (PDF)
  • Orally Active Inhibitor of Akt Pathway

• SR16157: Novel Drug for the Treatment of Breast Cancer (PDF)
  • Dual Acting Sulfatase Inhibitor and SERM

• SR16388: Novel Steroid for the Treatment of Cancer (PDF)
  • Apoptosis Inducing, Antiangiogenic Steroid

For additional information, please contact:
Edward Spack, Ph.D.
Senior Director, Business Development
650-859-3064 ; edward.spack@sri.com

       Last Updated Sep 14, 2006